![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
September 14, 2020
Welcome to the News From ECOG-ACRIN blog; COVID-19 month six reflections; clinical trial enrollment continues to improve; EA Cancer Research Advocates Committee adds five new members
September 14, 2020
This phase II trial by EA's Cancer Control and Survivorship Committee is comparing two promising pneumonitis treatments for patients receiving PD-1/PD-L1 therapy
September 14, 2020
A second interim analysis of this international adjuvant study for HR+, HER2- early breast cancer demonstrates that there is little chance of palbociclib reducing the risk of recurrence
September 14, 2020
Up to eight young investigators will present their work at the annual Young Investigator Symposium, taking place during the Virtual Fall 2020 Group Meeting
September 14, 2020
This is the only study that is currently designed to test the ability to improve long-term outcomes by refining early-setting triple-negative breast cancer chemotherapy without exposing ALL patients to more toxicity preoperatively